Current Research Studies

Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Participants with Cholestatic Pruritus

MRX-802

  • Condition(s): Other
  • Phase: III
  • Clinicaltrials.gov ID: NCT06553768

What is the goal of the study?

The study is a multicenter, randomized, double-blind, placebo-controlled study followed by open-label dosing. This drug is already FDA approved for the treatment of cholestatic pruritus in children with Alagille's Syndrome. This study is designed to evaluate the efficacy and safety of Maralixbat, an IBAT inhibitor, in patients with cholestatic pruritus with variable underlying disease who do not have commercial access to an IBAT inhibitor.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: